Paper Details

  1. Home
  2. Paper Details

Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys.

Author: EpsteinDavid Lee, KiriharaTomoko, MatsugiTakeshi, RaoPonugoti Vasantha, ShimazakiAtsushi, TajimaHisashi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

SA12590, a new oxime-derivative of the ethacrynic acid (ECA) derivative SA9000, was found to have ocular hypotensive effects in cats and monkeys without corneal toxicity. SA12590 may be a potential new ocular hypotensive drug.
Paper Details　
Original Abstract of the Article :
To evaluate the pharmacological characteristics of SA12590, a new oxime-derivative of the ethacrynic acid (ECA) derivative SA9000, we examined both its ocular hypotensive effects (in ocular normotensive cats and cynomolgus monkeys) and its potential corneal toxicity (in rats). A 50 microl topical ad...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1248/bpb.30.1445

データ提供：米国国立医学図書館（NLM）

SA12590: A Potential New Ocular Hypotensive Drug

This research explores the potential of SA12590, a new derivative of ethacrynic acid, as a treatment for high intraocular pressure (IOP), a major risk factor for glaucoma. Think of it as a desert physician searching for a remedy to heal a vision-threatening condition, carefully evaluating the effects of a new medicine. The researchers investigated the ocular hypotensive effects of SA12590 in cats and monkeys, finding that it significantly reduced IOP without causing corneal toxicity. This research suggests that SA12590 may be a promising new drug candidate for managing IOP and potentially preventing glaucoma.

SA12590: A Promising New Ocular Hypotensive Drug

This study suggests that SA12590, a new derivative of ethacrynic acid, may have potential as a new ocular hypotensive drug. Its efficacy in reducing IOP without causing corneal toxicity suggests that it could be a valuable treatment option for individuals with high IOP.

Protecting Vision

Glaucoma is a leading cause of blindness worldwide. Early diagnosis and treatment are crucial for preventing vision loss. This research highlights the ongoing need to develop new and effective therapies for managing IOP and preserving vision.

Dr. Camel's Conclusion

This study offers hope for individuals struggling with high intraocular pressure, exploring the potential of SA12590 as a promising new treatment option. It underscores the importance of ongoing research to develop innovative therapies for managing IOP and preserving vision.

Date :
  1. Date Completed 2007-09-21
  2. Date Revised 2019-07-20
Further Info :

Pubmed ID

17666801

DOI: Digital Object Identifier

10.1248/bpb.30.1445

Related Literature

Article Analysis
・Effects of ethacrynic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.